Three phase 1/2, open-label studies of cereblon e3 ligase modulator (celmod)-based regimens in newly diagnosed (nd) or relapsed/refractory (r/r) non-hodgkin lymphoma (nhl)

F. Morschhauser, G.S. Nowakowski,Guillaume Cartron, V. Kesanakurthy, A. Gkasiamis,P. Patah, R. Delarue, T. Wang, J. Li, D. Xian,Christopher P. Fox,Peter Martin

Hematological Oncology(2021)

引用 0|浏览5
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要